Toolkit · Commercial

The Advertising and Marketing Law Toolkit

15 U.S.C. § 45

Type
Toolkit
Jurisdiction
National
Date
2024-11-14
Topic
Commercial

A research and resource map for advertising and marketing counsel, agency lawyers, regulators, and litigators on both sides of a false advertising dispute. Ten pillars organize the field: Section 5 deception and unfairness, claim identification and the net impression, puffery and the reasonable consumer, prior substantiation and establishment claims, clear and conspicuous disclosure, endorsements and consumer reviews, the specialty regimes for origin and environmental and health claims, pricing and fees and negative option marketing, competitor enforcement through the Lanham Act and the National Advertising Division, and consumer enforcement through state UDAP class actions with the remedial landscape after AMG Capital. Each pillar states the doctrine, names the controlling authorities, identifies the trap competent practitioners fall into, explains its second-order consequence, and points deeper. An authority shelf collects the statutes, rules and guides, leading cases, and secondary sources including the standard treatises and the agency guidance documents that function as operative law. Two appendices supply a claim-type to substantiation matrix and a forum selection and exposure triage sheet.

The Advertising and Marketing Law Toolkit

Commercial > Advertising and Marketing | Published 14 November 2024 - Updated 12 July 2026 | UpLaw - uplaw.us

In brief. Ask three questions in order: what does the ad convey, is that message material, and could you prove it before it ran? Then ask a fourth that decides your exposure: is the governing instrument a rule or a guide? Rules carry civil penalties per violation. Guides tell you how you will lose.

Keywords: Section 5, deception, unfairness, net impression, Kraft, puffery, Pizza Hut, substantiation, Pfizer, establishment claims, Removatron, clear and conspicuous, Part 255, Part 465, Made in USA, Green Guides, ROSCA, dark patterns, NAD, Lanham Act, Lexmark, AMG, UDAP

How This Toolkit Is Organized

Ten pillars, each giving the doctrine, the anchors, the trap and its second order consequence, and where to go deeper. Then the authority shelf, then two appendices: a claim-type to substantiation matrix and a forum and exposure triage sheet.

The narrative entry point is Puffery, Substantiation, and the Reasonable Consumer: Where Ad Claims Actually Fail. The doctrinal treatment is Advertising and Marketing Law: A Comprehensive Guide to Substantiation, Endorsements, and Claims. The operational sequence is Clearing an Advertising Campaign: A Substantiation and Disclosure Checklist.

Running parties throughout this cluster: Halcyon Home Goods, Inc. (fictional), advertiser; Quill & Ember (fictional), its agency; Meridian Air Systems, LLC (fictional), its competitor; Brightline Testing Laboratories (fictional), its lab; and Devon Ashcroft (fictional), its lead creator.

Pillar 1 — Section 5: Deception and Unfairness

Doctrine. Section 5 prohibits deceptive practices — representations, omissions, or practices likely to mislead a reasonable consumer on a material point — and separately prohibits unfair practices causing substantial, unavoidable injury not outweighed by countervailing benefits. Neither theory requires intent, reliance, or proof that any consumer was actually deceived.

Anchors. 15 U.S.C. § 45 (§ 5) and § 45(n) (unfairness codified); 15 U.S.C. § 52 (§ 12, food/drug/device/cosmetic advertising). Deception Policy Statement, appended to Cliffdale Associates, Inc., 103 F.T.C. 110 (1984). Unfairness Policy Statement (1980); FTC v. Sperry & Hutchinson Co., 405 U.S. 233 (1972); American Financial Services Ass'n v. FTC, 767 F.2d 957 (D.C. Cir. 1985); FTC v. Neovi, Inc., 604 F.3d 1150 (9th Cir. 2010); FTC v. Wyndham Worldwide Corp., 799 F.3d 236 (3d Cir. 2015). FTC v. Standard Education Society, 302 U.S. 112 (1937).

Trap. Treating "likely to mislead" as a synonym for "false." It is a far lower threshold, satisfied by a true statement that conveys an untrue impression and by an omission that leaves a half-truth standing.

Trap, second order. Missing the unfairness case entirely. When the problem is design rather than copy — pre-checked enrollment, obstructed cancellation, false urgency, asymmetric flows — there may be nothing false anywhere in the advertisement, and a review that only reads text will clear a campaign that is squarely unlawful.

Go deeper: Guide Parts II–III

Pillar 2 — Claim Identification and the Net Impression

Doctrine. The advertiser is responsible for every message the ad conveys, express or implied, judged on the net impression of the whole — words, images, demonstrations, sequence, juxtaposition, and material omissions.

Anchors. FTC v. Colgate-Palmolive Co., 380 U.S. 374 (1965) (undisclosed mock-up used to prove a claim). Kraft, Inc. v. FTC, 970 F.2d 311 (7th Cir. 1992) (Commission may find facially evident implied claims by reasoned analysis, without extrinsic evidence). Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer Pharmaceuticals Co., 290 F.3d 578 (3d Cir. 2002) and Time Warner Cable, Inc. v. DIRECTV, Inc., 497 F.3d 144 (2d Cir. 2007) (falsity by necessary implication). National Commission on Egg Nutrition v. FTC, 570 F.2d 157 (7th Cir. 1977).

Trap. Inventorying only the claims someone wrote down. Implied claims are unwritten, therefore unsubstantiated, therefore the exposure. The test measured what the test measured; the ad claimed what the consumer heard — that gap is the whole practice area.

Trap, second order. Claim broadening by layout. An accurate attribute number placed beside an aspirational image, or a vague superlative placed above a comparison chart, creates a new claim requiring new proof. Reviewing copy without reviewing art misses it every time, which is also how flag imagery becomes an origin claim and a green leaf becomes an environmental one.

Go deeper: Guide Part IV · Checklist Phase 2

Pillar 3 — Puffery and the Reasonable Consumer

Doctrine. Vague, subjective, unmeasurable commendation conveys no factual claim and is not actionable. The audience is the reasonable member of the group the advertisement targets, and the standard tightens where the audience is vulnerable.

Anchors. Pizza Hut, Inc. v. Papa John's International, Inc., 227 F.3d 489 (5th Cir. 2000). Southland Sod Farms v. Stover Seed Co., 108 F.3d 1134 (9th Cir. 1997). Castrol Inc. v. Pennzoil Co., 987 F.2d 939 (3d Cir. 1993). Clorox Co. Puerto Rico v. Procter & Gamble Commercial Co., 228 F.3d 24 (1st Cir. 2000). Charles of the Ritz Distributing Corp. v. FTC, 143 F.2d 676 (2d Cir. 1944). Front-label line: Williams v. Gerber Products Co., 552 F.3d 934 (9th Cir. 2008); Mantikas v. Kellogg Co., 910 F.3d 633 (2d Cir. 2018); Bell v. Publix Super Markets, Inc., 982 F.3d 468 (7th Cir. 2020); contrast Moore v. Trader Joe's Co., 4 F.4th 874 (9th Cir. 2021); Becerra v. Dr Pepper/Seven Up, Inc., 945 F.3d 1225 (9th Cir. 2019); synthesis in McGinity v. Procter & Gamble Co., 69 F.4th 1093 (9th Cir. 2023).

Trap. Treating puffery as an immunity. It is a claim-identification argument — an assertion that the ad conveys no factual claim at all — and it collapses the moment context supplies one, as Pizza Hut itself demonstrates in two steps.

Trap, second order. Winning on puffery is a commercial defeat. The defense is a sworn position that the client's central marketing promise was legally meaningless, which the marketing team will not accept and a jury may not like. A back label can clarify an ambiguous front label; it can never contradict an unambiguous one.

Go deeper: Article Parts III–IV

Pillar 4 — Prior Substantiation and Establishment Claims

Doctrine. An advertiser must possess and rely upon a reasonable basis for each objective claim at the time of dissemination. Making a claim without that basis is itself deceptive, even if the claim is true. Health, safety, and efficacy claims require competent and reliable scientific evidence, and a claim that something is "proven" requires evidence of the type and quantity the word promises.

Anchors. In re Pfizer, Inc., 81 F.T.C. 23 (1972); Advertising Substantiation Policy Statement, appended to Thompson Medical Co., 104 F.T.C. 648 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986). Removatron International Corp. v. FTC, 884 F.2d 1489 (1st Cir. 1989). FTC v. Pantron I Corp., 33 F.3d 1088 (9th Cir. 1994). FTC v. QT, Inc., 512 F.3d 858 (7th Cir. 2008). FTC v. National Urological Group, Inc., 645 F. Supp. 2d 1167 (N.D. Ga. 2008), aff'd, 356 F. App'x 358 (11th Cir. 2009). FTC v. Direct Marketing Concepts, Inc., 624 F.3d 1 (1st Cir. 2010). POM Wonderful, LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015); Central Hudson Gas & Electric Corp. v. Public Service Commission, 447 U.S. 557 (1980). FTC Health Products Compliance Guidance (2022).

Trap. The lab summary memo. It says the product performed; the underlying protocol shows maximum settings, a sealed chamber, a single pass, and an endpoint unrelated to the consumer benefit claimed. Always read the protocol, never the summary.

Trap, second order. The establishment claim nobody priced. "Clinically proven" costs nothing to write and converts a marketing adjective into a stipulation about your evidence — and hands a competitor the easier Lanham Act theory of showing the cited tests do not support the claim, without disproving anything. Castrol Inc. v. Quaker State Corp., 977 F.2d 57 (2d Cir. 1992).

Go deeper: Guide Part V · Checklist Phase 3

Pillar 5 — Clear and Conspicuous Disclosure

Doctrine. Where a claim is true but incomplete, the qualifying information must be difficult to miss and easily understandable — same modality as the claim, proximate to it, unavoidable, of sufficient duration, uncontradicted, and in ordinary language.

Anchors. 16 C.F.R. § 255.0(f); FTC .com Disclosures: How to Make Effective Disclosures in Digital Advertising (2013); FTC v. Cyberspace.com, LLC, 453 F.3d 1196 (9th Cir. 2006). Bringing Dark Patterns to Light, FTC Staff Report (2022). Zauderer v. Office of Disciplinary Counsel, 471 U.S. 626 (1985) and National Institute of Family & Life Advocates v. Becerra, 585 U.S. 755 (2018) (limits on compelled disclosure).

Trap. Approving the design comp rather than the rendered asset. A disclosure legible at 200% zoom in a design file is frequently invisible in-feed on a phone, and the rendered asset is what a regulator will look at.

Trap, second order. Believing a disclaimer can rescue a false claim. It cannot. It can qualify a true-but-incomplete one. And where the chosen format genuinely cannot carry the required disclosure — a six-second bumper, a smart-speaker read, a banner — the correct answer is to change the claim or drop the format, not to shrink the type.

Go deeper: Guide Part VII · Checklist Phase 5

Pillar 6 — Endorsements, Influencers, and Consumer Reviews

Doctrine. An advertiser is liable for claims made through endorsers as if it made them itself; material connections must be disclosed clearly and conspicuously; depicted results must be generally achievable; and fabricating, buying, or suppressing consumer reviews is now prohibited by rule.

Anchors. Endorsement Guides, 16 C.F.R. Part 255 (2023 revision) — § 255.1 (honest opinion, advertiser liability), § 255.2 (consumer endorsements; "results not typical" does not cure), § 255.3 (experts), § 255.5 (material connections), § 255.6 (children). Rule on the Use of Consumer Reviews and Testimonials, 16 C.F.R. Part 465 (2024) — §§ 465.2 (fake reviews), 465.4 (sentiment-conditioned incentives), 465.5 (insider reviews), 465.6 (controlled review sites), 465.7 (suppression), 465.8 (fake social indicators). Consumer Review Fairness Act, 15 U.S.C. § 45b. Agency liability: Standard Oil Co. of California v. FTC, 577 F.2d 653 (9th Cir. 1978). Individual liability: FTC v. Publishing Clearing House, Inc., 104 F.3d 1168 (9th Cir. 1997).

Trap. A perfect influencer contract with no monitoring. The Guides do not require perfection; they require a program that works — contract, claim sheet, training, monitoring, and correction records — and evidence of it. A contract alone proves the brand knew the rules and did nothing to enforce them.

Trap, second order. Underrating Part 465 because it looks like housekeeping. It is a rule, so violations carry civil penalties per violation and support consumer redress under 15 U.S.C. § 57b — an entirely different order of exposure than a guide. The asymmetric "verification queue" that holds negative reviews for review while positive ones post instantly is suppression under § 465.7, and it is documented in a workflow tool with timestamps.

Go deeper: Guide Parts VIII–IX · Checklist Phases 6–7

Pillar 7 — Origin, Environmental, and Health Claims

Doctrine. Three specialty regimes carry their own standards: unqualified U.S.-origin claims require "all or virtually all" domestic content; environmental claims must be attribute-specific and satisfy the Green Guides; and health claims must satisfy both FTC substantiation and the FDA labeling regime, with disease claims converting ordinary products into unapproved drugs.

Anchors. Made in USA Labeling Rule, 16 C.F.R. Part 323 (penalties); Enforcement Policy Statement on U.S. Origin Claims (1997); Textile and Wool Acts, 16 C.F.R. Part 303. Green Guides, 16 C.F.R. Part 260; California Environmental Marketing Claims Act, Cal. Bus. & Prof. Code § 17580. FDCA: 21 U.S.C. § 321(g) (drug definition), 21 U.S.C. § 343(r) (nutrient content and health claims); FTC Health Products Compliance Guidance (2022). POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014) (FDCA compliance does not preclude a Lanham Act claim).

Trap. Assuming the claim is in the copy. A flag is an origin claim, a green leaf on kraft-brown board is an environmental claim, and a photograph of a sleeping child beside a performance number is a health claim. None of them appear in the script.

Trap, second order. Clearing to the federal standard. State environmental marketing statutes — chasing-arrows restrictions, carbon-claim disclosure obligations — and state origin statutes are stricter than the federal baseline and carry private rights of action. Greenwashing is now a mature plaintiffs' practice, and the Green Guides are a guide while the Made in USA rule carries penalties.

Go deeper: Guide Part X · FDA Regulation of Food, Drugs, Devices, and Cosmetics

Pillar 8 — Pricing, Fees, and Negative Option Marketing

Doctrine. A reference price must have been a bona fide price actually offered; "free" requires that the tied purchase be unchanged in price and quality; mandatory fees must be disclosed in the advertised total where a rule or state statute requires it; and any negative option feature requires pre-billing disclosure, express informed consent, and a simple cancellation mechanism.

Anchors. Guides Against Deceptive Pricing, 16 C.F.R. Part 233; Bait Advertising, 16 C.F.R. Part 238; Use of "Free," 16 C.F.R. Part 251; Unfair or Deceptive Fees Rule, 16 C.F.R. Part 464; Mail, Internet, or Telephone Order Merchandise Rule, 16 C.F.R. Part 435. ROSCA, 15 U.S.C. §§ 8401–8405; Negative Option Rule, 16 C.F.R. Part 425; Telemarketing Sales Rule, 16 C.F.R. Part 310. Custom Communications, Inc. v. FTC, No. 24-3137 (8th Cir. July 8, 2025) (vacating the 2024 "click to cancel" amendments for failure to issue the preliminary regulatory analysis required by 15 U.S.C. § 57b-3).

Trap. Reading the Eighth Circuit's vacatur as deregulation. ROSCA, Section 5, the pre-existing Negative Option Rule, and every state auto-renewal statute survived untouched. Nothing about compliant subscription design changed.

Trap, second order. Building jurisdiction-specific checkout flows. They fail in practice, because promotions calendars and growth experiments do not respect state lines. Build one flow to the strictest state standard — pre-enrollment disclosure adjacent to the consent control, unchecked affirmative consent, post-purchase acknowledgment, advance renewal reminders, and online cancellation in the same medium as enrollment — and deploy it everywhere. Reference-price claims fail the same way: the proof is a query against the client's own pricing system.

Go deeper: Guide Parts XI–XII · Checklist Phases 9–10

Pillar 9 — Competitor Enforcement: Lanham Act and NAD

Doctrine. A commercial party injured by a competitor's false or misleading advertising may sue under Section 43(a)(1)(B) for injunctive relief, damages, and profits — or challenge the claim at the National Advertising Division, which decides substantiation disputes on written submissions in months rather than years.

Anchors. 15 U.S.C. § 1125(a)(1)(B); remedies at 15 U.S.C. § 1117; irreparable-harm presumption restored by the Trademark Modernization Act of 2020, 15 U.S.C. § 1116(a). Lexmark International, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014) (zone of interests plus proximate cause). Johnson & Johnson * Merck Consumer Pharmaceuticals Co. v. Smithkline Beecham Corp., 960 F.2d 294 (2d Cir. 1992) (implied falsity needs consumer evidence). Castrol Inc. v. Quaker State Corp., 977 F.2d 57 (2d Cir. 1992). Gordon & Breach Science Publishers S.A. v. American Institute of Physics, 859 F. Supp. 1521 (S.D.N.Y. 1994) ("commercial advertising or promotion"). Verisign, Inc. v. XYZ.COM LLC, 848 F.3d 292 (4th Cir. 2017). Romag Fasteners, Inc. v. Fossil, Inc., 590 U.S. 212 (2020). Warner-Lambert Co. v. FTC, 562 F.2d 749 (D.C. Cir. 1977) (corrective advertising). BBB National Programs NAD/NARB Procedures; CARU Guidelines.

Trap. Reading Lexmark as purely liberalizing. It abolished the circuits' prudential standing tests and freed non-competitors with genuine commercial injury to sue — but it tightened proximate causation, and claims fail where the alleged lost sales are derivative or speculative rather than traceable to the challenged statement.

Trap, second order. Dismissing an NAD challenge as low-stakes because there are no damages and no discovery. NAD produces a published decision, a referral to the FTC for non-participation or non-compliance, and a factual record a class-action plaintiff will quote in the first paragraph of the complaint. For a challenger, the SWIFT track resolves a single well-defined issue in roughly twenty business days at a fraction of litigation cost.

Go deeper: Guide Parts VI and XIV · Temporary Restraining Orders and Preliminary Injunctions

Pillar 10 — Consumer Enforcement, Remedies, and Who Pays

Doctrine. Consumers cannot sue under the Lanham Act; they sue under state UDAP statutes, usually as a class, usually on a price-premium damages theory. The FTC enforces Section 5 — but after AMG, its monetary remedies run through rules, orders, and penalty offense authority rather than through Section 13(b).

Anchors. AMG Capital Management, LLC v. FTC, 593 U.S. 67 (2021) (no equitable monetary relief under 15 U.S.C. § 53(b)). Redress under 15 U.S.C. § 57b; civil penalties under § 45(m)(1)(A); penalty offense notices under § 45(m)(1)(B); order violations under § 45(l); Magnuson-Moss rulemaking under 15 U.S.C. § 57a. State UDAP: Cal. Bus. & Prof. Code §§ 17200 and 17500 and Civ. Code § 1750; N.Y. Gen. Bus. Law §§ 349–350; Mass. Gen. Laws ch. 93A. Kwikset Corp. v. Superior Court, 51 Cal. 4th 310 (2011). TransUnion LLC v. Ramirez, 594 U.S. 413 (2021). Comcast Corp. v. Behrend, 569 U.S. 27 (2013); Tyson Foods, Inc. v. Bouaphakeo, 577 U.S. 442 (2016); Briseno v. ConAgra Foods, Inc., 844 F.3d 1121 (9th Cir. 2017) versus Carrera v. Bayer Corp., 727 F.3d 300 (3d Cir. 2013).

Trap. Treating a penalty offense notice as correspondence. It is not an accusation; it is the deliberate construction of a penalty predicate under § 45(m)(1)(B), so that subsequent conduct with actual knowledge becomes penalty-bearing. Recipients should treat it as an urgent compliance project with a documented remediation record.

Trap, second order. Assuming the advertiser is the only defendant. The agency is exposed where it participated in creating the ad and knew or should have known — Standard Oil Co. of California v. FTC — and individual officers are exposed where they had authority to control the conduct plus knowledge or reckless indifference, FTC v. Publishing Clearing House. Endorsers, affiliate networks, lead generators, and platforms making their own claims are all reachable. Conflicts arise fast; identify them before the joint defense agreement is drafted.

Go deeper: Guide Part XIV · Checklist Phase 12

The Authority Shelf

Statutes

Rules and guides

Agency guidance that functions as operative law

  • FTC Policy Statement on Deception (1983) · Policy Statement on Unfairness (1980) · Advertising Substantiation Policy Statement (1984) · Statement of Policy Regarding Comparative Advertising (1979) · Enforcement Policy Statement on U.S. Origin Claims (1997) · .com Disclosures (2013) · Health Products Compliance Guidance (2022) · Disclosures 101 for Social Media Influencers · Bringing Dark Patterns to Light (2022) · FTC Endorsement Guides FAQs ("The FTC's Endorsement Guides: What People Are Asking")

Leading cases — FTC side

  • FTC v. Standard Education Society, 302 U.S. 112 (1937) · Charles of the Ritz Distributing Corp. v. FTC, 143 F.2d 676 (2d Cir. 1944) · FTC v. Colgate-Palmolive Co., 380 U.S. 374 (1965) · FTC v. Sperry & Hutchinson Co., 405 U.S. 233 (1972) · In re Pfizer, Inc., 81 F.T.C. 23 (1972) · National Commission on Egg Nutrition v. FTC, 570 F.2d 157 (7th Cir. 1977) · Warner-Lambert Co. v. FTC, 562 F.2d 749 (D.C. Cir. 1977) · Standard Oil Co. of Cal. v. FTC, 577 F.2d 653 (9th Cir. 1978) · Cliffdale Associates, Inc., 103 F.T.C. 110 (1984) · Thompson Medical Co., 104 F.T.C. 648 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986) · American Financial Services Ass'n v. FTC, 767 F.2d 957 (D.C. Cir. 1985) · Removatron Int'l Corp. v. FTC, 884 F.2d 1489 (1st Cir. 1989) · Kraft, Inc. v. FTC, 970 F.2d 311 (7th Cir. 1992) · FTC v. Pantron I Corp., 33 F.3d 1088 (9th Cir. 1994) · FTC v. Publishing Clearing House, Inc., 104 F.3d 1168 (9th Cir. 1997) · In re Telebrands Corp., 140 F.T.C. 278 (2005), aff'd, 457 F.3d 354 (4th Cir. 2006) · FTC v. Cyberspace.com, LLC, 453 F.3d 1196 (9th Cir. 2006) · FTC v. QT, Inc., 512 F.3d 858 (7th Cir. 2008) · FTC v. Neovi, Inc., 604 F.3d 1150 (9th Cir. 2010) · FTC v. Direct Marketing Concepts, Inc., 624 F.3d 1 (1st Cir. 2010) · POM Wonderful, LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015) · FTC v. Wyndham Worldwide Corp., 799 F.3d 236 (3d Cir. 2015) · AMG Capital Management, LLC v. FTC, 593 U.S. 67 (2021)

Leading cases — competitor and consumer side

  • Castrol Inc. v. Quaker State Corp., 977 F.2d 57 (2d Cir. 1992) · Johnson & Johnson * Merck v. Smithkline Beecham Corp., 960 F.2d 294 (2d Cir. 1992) · Castrol Inc. v. Pennzoil Co., 987 F.2d 939 (3d Cir. 1993) · Southland Sod Farms v. Stover Seed Co., 108 F.3d 1134 (9th Cir. 1997) · Clorox Co. P.R. v. Procter & Gamble Commercial Co., 228 F.3d 24 (1st Cir. 2000) · Pizza Hut, Inc. v. Papa John's Int'l, Inc., 227 F.3d 489 (5th Cir. 2000) · Novartis Consumer Health v. Johnson & Johnson-Merck, 290 F.3d 578 (3d Cir. 2002) · Time Warner Cable, Inc. v. DIRECTV, Inc., 497 F.3d 144 (2d Cir. 2007) · Williams v. Gerber Products Co., 552 F.3d 934 (9th Cir. 2008) · Kwikset Corp. v. Superior Court, 51 Cal. 4th 310 (2011) · Lexmark Int'l, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014) · POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014) · Verisign, Inc. v. XYZ.COM LLC, 848 F.3d 292 (4th Cir. 2017) · Mantikas v. Kellogg Co., 910 F.3d 633 (2d Cir. 2018) · Becerra v. Dr Pepper/Seven Up, Inc., 945 F.3d 1225 (9th Cir. 2019) · Romag Fasteners, Inc. v. Fossil, Inc., 590 U.S. 212 (2020) · Bell v. Publix Super Markets, Inc., 982 F.3d 468 (7th Cir. 2020) · Moore v. Trader Joe's Co., 4 F.4th 874 (9th Cir. 2021) · McGinity v. Procter & Gamble Co., 69 F.4th 1093 (9th Cir. 2023)

Secondary sources

  • J. Thomas McCarthy, McCarthy on Trademarks and Unfair Competition — chapter 27 is the standard treatment of § 43(a) false advertising
  • Louis Altman & Malla Pollack, Callmann on Unfair Competition, Trademarks and Monopolies
  • Jef I. Richards and Ross D. Petty, and the ABA Antitrust Law Section's Consumer Protection Law Developments — the best single volume on FTC practice
  • ABA Section of Antitrust Law, Consumer Protection Handbook; Antitrust Law Journal and Antitrust Magazine consumer-protection issues
  • Journal of Public Policy & Marketing — the leading empirical literature on consumer perception and copy testing, which is what survey experts cite
  • Food and Drug Law Journal; Loyola Consumer Law Review; NYU Journal of Intellectual Property & Entertainment Law
  • BBB National Programs — NAD/NARB case decisions and annual reports; CARU guidelines; DSSRC decisions
  • FTC Business Blog and Bureau of Consumer Protection business guidance — the fastest signal on enforcement priorities
  • Truth in Advertising (TINA.org) — an advocacy organization whose complaints frequently precede enforcement
  • National Association of Attorneys General multistate consumer protection materials

Appendix A — Claim Type to Substantiation Matrix

Identify the claim type; the required support follows. Plead or clear against every applicable row.

Claim as consumers read it Type Substantiation required
"Removes 99.97% of allergens" Quantified performance Test at conditions matching consumer use; protocol must match claim scope
"Clinically proven to help you breathe easier" Establishment Evidence of the type and quantity "clinically proven" communicates — controlled, blinded, matched endpoint
"Helps support respiratory health" Health / structure-function Competent and reliable scientific evidence; FDA notification and disclaimer if a supplement
"Treats asthma" Disease claim Drug approval; otherwise unlawful regardless of evidence
"The most advanced purifier you can buy" (standalone) Puffery None — unless context supplies a factual comparison
"Quieter than Meridian" Comparative Head-to-head test, current model, realistic settings
"#1 selling purifier" Superiority / market Metric, market, period, and source, with an expiration date
"Up to 40% quieter" Range An appreciable proportion of users achieve the maximum
"Made in USA" (or a flag) Origin All or virtually all domestic; else a qualified claim
"Recyclable" Environmental Facilities available to a substantial majority where sold
"Eco-friendly" General environmental benefit Effectively unsubstantiable; replace with a specific attribute
"Was $799, now $399" Reference price A bona fide price actually offered for a substantial recent period
"Free 30-day trial" Negative option Pre-billing disclosure, express informed consent, simple cancellation
"4.8 stars from 4,100 reviews" Social proof Reviews genuine, incentives not sentiment-conditioned, no suppression, methodology accurate
"I've used this for years" (creator) Endorsement True experience, honest opinion, disclosed material connection, substantiated underlying claim
"Doctor recommended" Establishment / expert A survey or evaluation an actual expert would conduct, documented

Appendix B — Forum and Exposure Triage

Run this before advising on risk. The answers determine both the cost and the currency of the exposure.

  1. Is the governing instrument a rule or a guide? Rules — Parts 465, 323, 425, 464, 435, 310, 312 — carry civil penalties per violation and support redress under 15 U.S.C. § 57b. Guides do not.
  2. Has the client received a penalty offense notice under § 45(m)(1)(B)? If so, the same conduct is now penalty-bearing.
  3. Is the claim an establishment claim? If yes, the competitor's path is short and the evidentiary burden is on your file.
  4. Does the substantiation predate dissemination, and can you prove it with dated records?
  5. Is a competitor named, shown, or identifiable? If yes, expect NAD or a Lanham Act demand within one quarter.
  6. Does a challenger have Lexmark standing — a commercial interest in reputation or sales, proximately injured?
  7. Is the falsity literal or implied? Implied falsity means a survey, which means six figures and months.
  8. Would NAD be a better forum — for the challenger (fast, cheap, expert) or for the advertiser (no damages, no discovery, private until decided)?
  9. Is there a class-actionable state UDAP theory, and does a price premium damages model fit the liability theory under Comcast?
  10. Which state statutes are stricter than the federal baseline — auto-renewal, environmental marketing, price comparison, fee disclosure — and has the campaign been cleared against them?
  11. Does the audience include children, triggering COPPA, CARU, and state design codes?
  12. Who else is exposed — the agency under Standard Oil, individual officers under Publishing Clearing House, endorsers, affiliate networks — and where are the conflicts?

Related Documents

Articles

Guides

Checklists

Toolkits